Departamento de Química Física, Instituto de Biotecnología e Unidad de Excelencia de Química Aplicada a Biomedicina y Medioambiente (UEQ), Facultad de Ciencias, Universidad de Granada, 18071 Granada, Spain.
INSERM U1109, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
J Mol Biol. 2020 Sep 18;432(20):5577-5592. doi: 10.1016/j.jmb.2020.08.010. Epub 2020 Aug 19.
One of the therapeutic strategies in HIV neutralization is blocking membrane fusion. In this process, tight interaction between the N-terminal and C-terminal heptad-repeat (NHR and CHR) regions of gp41 is essential to promote membranes apposition and merging. We have previously developed single-chain proteins (named covNHR) that accurately mimic the complete gp41 NHR region in its trimeric conformation. They tightly bind CHR-derived peptides and show a potent and broad HIV inhibitory activity in vitro. However, the extremely high binding affinity (sub-picomolar) is not in consonance with their inhibitory activity (nanomolar), likely due to partial or temporal accessibility of their target in the virus. Here, we have designed and characterized two single-chain covNHR miniproteins each encompassing one of the two halves of the NHR region and containing two of the four sub-pockets of the NHR crevice. The two miniproteins fold as trimeric helical bundles as expected but while the C-terminal covNHR (covNHR-C) miniprotein is highly stable, the N-terminal counterpart (covNHR-N) shows only marginal stability that could be improved by engineering an internal disulfide bond. Both miniproteins bind their respective complementary CHR peptides with moderate (micromolar) affinity. Moreover, the covNHR-N miniproteins can access their target in the context of trimeric native envelope proteins and show significant inhibitory activity for several HIV pseudoviruses. In contrast, covNHR-C cannot bind its target sequence and neither inhibits HIV, indicating a higher vulnerability of C-terminal part of CHR. These results may guide the development of novel HIV inhibitors targeting the gp41 CHR region.
HIV 中和的治疗策略之一是阻断膜融合。在这个过程中,gp41 的 N 端和 C 端七肽重复(NHR 和 CHR)区域之间的紧密相互作用对于促进膜附着和融合至关重要。我们之前开发了一种单链蛋白(命名为 covNHR),它能准确模拟 gp41 NHR 区域的三聚体构象。它们能紧密结合 CHR 衍生的肽段,并在体外表现出强大而广谱的 HIV 抑制活性。然而,极高的结合亲和力(亚皮摩尔级)与它们的抑制活性(纳摩尔级)不一致,这可能是由于它们的靶标在病毒中的部分或暂时可及性。在这里,我们设计并表征了两种单链 covNHR 小蛋白,每种小蛋白都包含 NHR 区域的两个半区之一,并含有 NHR 裂缝的四个亚袋中的两个。这两种小蛋白如预期的那样折叠成三聚体螺旋束,但 C 端 covNHR(covNHR-C)小蛋白高度稳定,而 N 端对应物(covNHR-N)仅显示出较小的稳定性,通过工程设计一个内部二硫键可以改善其稳定性。这两种小蛋白都能以中等亲和力(微摩尔级)结合各自互补的 CHR 肽段。此外,covNHR-N 小蛋白可以在三聚体天然包膜蛋白的背景下接触到它们的靶标,并对几种 HIV 假病毒表现出显著的抑制活性。相比之下,covNHR-C 不能结合其靶序列,也不能抑制 HIV,这表明 CHR 的 C 端部分更脆弱。这些结果可能为针对 gp41 CHR 区域的新型 HIV 抑制剂的开发提供指导。